News und Analysen
![Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row
Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), has been named the best in Mail Order Pharmacy customer satisfaction in the J.D. Power 2020 U.S. Pharmacy Study. It’s the third consecutive
![Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
![Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
![MorphoSys: Anlegern gefällt der Ausblick nicht, aber...](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
MorphoSys: Anlegern gefällt der Ausblick nicht, aber...
Erst am vergangenen Wochenende konnte das deutsche Biotechunternehmen MorphoSys (WKN: 663200) einen großen Erfolg verbuchen, nämlich die FDA-Zulassung des Krebsmittels Monjuvi. Daraufhin machte die
![MorphoSys: Anlegern gefällt der Ausblick nicht, aber...](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
MorphoSys: Anlegern gefällt der Ausblick nicht, aber...
Erst am vergangenen Wochenende konnte das deutsche Biotechunternehmen MorphoSys (WKN: 663200) einen großen Erfolg verbuchen, nämlich die FDA-Zulassung des Krebsmittels Monjuvi. Daraufhin machte die
![NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company
![Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
![FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
![FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
![Xencor to Present at Upcoming Investor Conferences](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
![STAAR Surgical Reports Second Quarter 2020 Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
STAAR Surgical Reports Second Quarter 2020 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
![Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
“We are very excited about our global
![Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its
![Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational
![LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
![LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
![Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth
![Novavax: Nachbörsliche Räuberpistole!](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Novavax: Nachbörsliche Räuberpistole!
Gestern Abend kam es nachbörslich zu einer wilden Berg- und Talfahrt bei der Aktie des US-amerikanischen Biotechunternehmens Novavax (WKN: A2PKMZ). Der Grund hierfür wirkt kurios.
Zunächst einmal
![Evotec: Vorstand streckt Fühler nach Antisense-Startup aus](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Evotec: Vorstand streckt Fühler nach Antisense-Startup aus
Evotec (WKN: 566480) geht seine nächste strategische Partnerschaft ein. So wurde, wie heute vermeldet, mit dem Marburger Next-Generation-Wirkstoffforscher Secarna Pharmaceuticals eine Kooperation im
![Xencor Reports Second Quarter 2020 Financial Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Xencor Reports Second Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
![Acadia Healthcare Reports Second Quarter 2020 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Acadia Healthcare Reports Second Quarter 2020 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2020.
The Company reported revenue of $750.3 million for the second quarter
![Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that it has raised $22.2 million (€ 19
![Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory
![Simulations Plus Announces Proposed Underwritten Public Offering](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
![Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at